Drug Type Biosimilar, Monoclonal antibody |
Synonyms Recombinant human TNF-α monoclonal antibody(Sinocelltech Group), 重组全人源抗肿瘤坏死因子α单抗 (神州细胞工程) + [3] |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (07 Jun 2023), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ankylosing Spondylitis | China | 07 Jun 2023 | |
Ankylosing Spondylitis | China | 07 Jun 2023 | |
Crohn Disease | China | 07 Jun 2023 | |
Crohn Disease | China | 07 Jun 2023 | |
Plaque psoriasis | China | 07 Jun 2023 | |
Polyarticular Juvenile Idiopathic Arthritis | China | 07 Jun 2023 | |
Polyarticular Juvenile Idiopathic Arthritis | China | 07 Jun 2023 | |
Rheumatoid Arthritis | China | 07 Jun 2023 | |
Rheumatoid Arthritis | China | 07 Jun 2023 | |
Uveitis | China | 07 Jun 2023 | |
Uveitis | China | 07 Jun 2023 |
NCT03927352 (Pubmed) Manual | Phase 3 | 367 | (lbnvexajtc) = bqqzyxtrxt zoliyctieq (sfrxdylizx ) | Similar | 17 Sep 2022 | ||
adalimumab | (lbnvexajtc) = zgfrfxjixc zoliyctieq (sfrxdylizx ) |